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Stem cell-based repair and regeneration for cardiac
regeneration following myocardial injury remain
unmet challenges largely due to low viability of cells
transplanted in the recipient sites. Accumulating
evidence has revealed that local existence of reactive
oxygen species (ROS) causes transplanted cell death
via both apoptosis and autophagy. Ham and
colleagues have identified let-7b as one of the
primary mediators for ROS-induced apoptosis and
autophagy of mesenchymal stem cells (MSCs)
through direct targeting of caspase-3. Importantly,
intramyocardial injection of let-7b-modified MSCs
significantly enhanced ventricular function and
facilitated myocardial repair by protecting
transplanted cells from apoptosis and autophagy in
the rat cardiac ischemia-reperfusion model. These
findings provide novel insights into the roles of
microRNA underlying stem cell survival following
in vivo delivery, and offer further evidence that
microRNA-modified MSC transplantation might be
an effective therapeutic approach for tissue repair
and regeneration.MicroRNA-mediated MSC therapy in myocardial
Introduction
Ischemic heart disease, one of the most common causes
of mortality worldwide, is characterized by myocardial
injury caused by oxygen deprivation which results in
cardiomyocyte death and impaired cardiac functions
and, if not properly managed, associates with mortal-
ity and morbidity. In past decades, stem cell-based* Correspondence: jhb@njmu.edu.cn
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science and it holds extraordinary translational poten-
tial as exemplified by the fact that mesenchymal stem
cells (MSCs) are an attractive source for cell-based
regenerative therapies in ischemic myocardial injury
on the basis of their multi-potent differentiation potential
and pro-angiogenic as well as immunomodulatory proper-
ties. However, one of the main obstacles for successful
stem cell-based regeneration is the low cellular viability
following transplantation, which remarkably compromises
therapeutic efficacy and outcomes. So there is a critical
and urgent need for the development of an optimized
strategy to promote cell survival in the recipient organs.
Recently in Stem Cell Research & Therapy, Ham and
colleagues [1] reported that the microRNA let-7b can
potently improve the survival of MSCs by inhibiting
apoptosis-related caspase-3 and enhance ventricular
function, microvessel density, and recovery of ischemic
myocardial injury. These findings further support the
key roles of microRNA in cardiac repair and regeneration
and provide novel evidence that microRNA-modified
MSC delivery might be a novel and viable treatment strat-
egy for ischemic heart disease.injury
Ischemic injury results in metabolic and structural
changes in affected cells because of deprivation of oxy-
gen and nutrition, inevitably leading to various types of
cell death such as apoptosis or autophagy. Various surgi-
cal and pharmacological approaches have been routinely
used to treat this disease in the clinic. However, such
approaches cannot efficiently save the cardiomyocytes
and restore the cardiac functions and this is largely due
to the limited regenerative potential of cardiac progeni-
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sibility to treat ischemic cardiac injury. Indeed, MSC
transplantation for this disease has been shown to be
highly beneficial and valuable to repair or regenerate
novel cardiomyocytes in the infarcted regions of the
heart in multiple animal models and selected clinical
patients. However, the harsh microenvironment in the
damaged heart significantly undermines the survival of
transplanted MSCs, thus greatly hampering their thera-
peutic efficacy and outcomes [2]. Therefore, optimizing
the approaches to augment engrafted cell survival and
function is a prerequisite to translate this therapeutic
strategy into clinics. Until now, several approaches have
been proposed to promote cell survival, including addi-
tions of growth factors, gene or microRNA modifica-
tions, and chemically activating signaling pathways in
MSCs before transplantation [3–5]. In particular, the
microRNA molecules, a novel class of endogenous post-
transcriptional regulators, stand out given their well-
established roles underlying cardiac repair [6]. Moreover,
these single-stranded RNAs have been shown to hold
tremendous potential as therapeutic targets and this is
largely due to the regulatory models of microRNA such
as simultaneous multiple targeting and modest regula-
tion of target gene expression [7]. Ham and colleagues
and others have shown that microRNA-modified MSCs
were more conducive and effective to repair of infarct
injury and improved heart function by enhancing trans-
planted cell survival and cardiomyogenic differentiation
[1, 2], thus highlighting the benefits and potential of
microRNA-modified MSCs in the treatment of ischemic
heart disease.
One of the important findings from the study by Ham
and colleagues is that the let-7b suppresses autophagic ac-
tivity in MSCs as shown by the fact that autophagy-related
genes Atg5, 7, and 12 and beclin-1 were significantly
downregulated in let-7b-overexpressed MSCs. Indeed,
mounting evidence indicates that autophagy has a double-
edged role in balancing cell survival and death. It occurs
primarily as the last survival mechanism to promote cell
longevity under conditions of cellular stress and is not
directly responsible for cell death. Under conditions of
nutrient deprivation, hypoxia, or inflammation, autopha-
gic degradation is one of the main strategies not only to
eliminate unwanted cytoplasmic materials but also to re-
cycle and subsequently re-use intracellular components
such as amino acids to promote cell survival. Interestingly,
autophagy can also trigger cell death, termed autophagic
cell death, which has been called non-apoptotic pro-
grammed cell death [8]. Although Ham and colleagues
reported that autophagic activity and the expression of
autophagy-related genes were attenuated upon exogenous
let-7b introduced into MSCs, it is still unclear how let-7b
regulates autophagy and whether autophagy attenuated bylet-7b is directly associated with MSC in vivo survival.
Therefore, it will be an interesting question for further
study to unravel the complex crosstalk among let-7b,
cellular apoptosis, and autophagy in MSCs under specific
conditions.
Notably, the study by Ham and colleagues has revealed
that delivery of let-7b-overexpressed MSCs markedly pro-
motes neovascularization in the infarcted myocardium
and functional recovery of damaged heart as assessed by
significantly increased ejection fraction and cardiac output
as well as approximately 10 % reduction of fibrotic
area in the let-7b-overexpressed MSC delivery group
as compared with control. Although self-renewal and
multi-differentiation potential of MSCs might be re-
sponsible for the improved cardiac repair, there is still
controversy about the precise mechanisms underlying
this process. Some researchers argue that MSCs can
differentiate into cardiomyocyte-like cells within distin-
guishable morphology and similar functions as compared
with native cardiomyocytes, but others argue that these
beneficial effects might be due to the paracrine signals or
factors secreted from MSCs. For example, MSC-mediated
tissue protection and repair are partially achieved through
the release of growth factors such as vascular endothelial
growth factor and basic fibroblast growth factor to pro-
mote angiogenesis. In addition, MSCs are able to create
an immunosuppressive microenvironment to alleviate
local inflammatory responses after transplantation [9]. In
the study by Ham and colleagues, the transient sur-
vival of MSCs through DAPI (4′,6-diamidino-2-pheny-
lindole) staining at 3 days after transplantation was
assessed. However, this seems relatively short, and in vivo
long-term cellular lineage tracking might offer more com-
pelling evidence to support the conclusion.
MSC-based therapy appears as a powerful therapeutic
approach in ischemic myocardial injury. However, more
studies are still needed to demonstrate MSCs as the
optimal cells to undergo cardiomyogenesis and sustain
long-time improvement of heart function. Recent study
has proposed a novel approach by using cell fusion to
support myocardial regeneration. Cardiochimeras formed
by fusion between cardiac-derived progenitor cells and
bone marrow-derived MSCs have enhanced reparative
potential in a mouse model of myocardial infarction.
Moreover, cardiac-derived progenitor cells are capable of
undergoing direct cardiomyogenic differentiation, whereas
MSCs provide protective immunomodulatory function
and growth factor release in a paracrine manner [10].
Conclusions
Ham and colleagues have provided evidence that let-7b
might promote cellular survival of MSCs both in vitro
and in vivo presumably by preventing cell apoptosis and
autophagy, thus enhancing cell survival in the treatment
Cheng et al. Stem Cell Research & Therapy  (2015) 6:216 Page 3 of 3of ischemic heart disease. It is worth mentioning that
research on the efficacy and safety of MSC-based ther-
apy in human cardiac repair is now under way. Although
many challenges lie ahead, we believe that MSC-based
therapy will be a sound approach for myocardial injury
in the near future.
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